Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures

被引:21
作者
Barzilay, Joshua I. [1 ,2 ]
Gao, Peggy [3 ]
Clase, Catherine M. [4 ]
Mente, Andrew [3 ,4 ]
Mann, Johannes F. E. [6 ,7 ]
Sleight, Peter [8 ]
Yusuf, Salim [3 ,4 ,5 ]
Teo, Koon K. [3 ,4 ,5 ]
机构
[1] Kaiser Permanente Georgia, Div Endocrinol, Atlanta, GA USA
[2] Emory Univ, Sch Med, Div Endocrinol, Atlanta, GA USA
[3] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[4] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[5] McMaster Univ, Dept Med, Hamilton, ON, Canada
[6] Kuratorium Heimdialyse Kidney Ctr, Munich, Germany
[7] Univ Erlangen Nurnberg, Dept Med 4, D-91054 Erlangen, Germany
[8] John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2013年 / 8卷 / 02期
基金
加拿大健康研究院;
关键词
BONE-MARROW PERFUSION; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; MINERAL DENSITY; OSTEOPOROSIS; TELMISARTAN; MICROALBUMINURIA; ENDOTHELIUM; INTOLERANT; MECHANISM;
D O I
10.2215/CJN.06640712
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives The microvascular circulation plays an important role in bone health. This study examines whether albuminuria, a marker of renal microvascular disease, is associated with incident hip and pelvic fractures. Design, setting, participants, & measurements This study reanalyzed data from the Ongoing Telmisartan Alone and in combination with Ramipril Global End Point Trial/Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Intolerant Subjects with Cardiovascular Disease trials, which examined the impact of renin angiotensin system blockade on cardiovascular outcomes (n=28,601). Albuminuria was defined as an albumin-to-creatinine ratio >= 30 mg/g (n=4597). Cox proportional hazards models were used to determine the association of albuminuria with fracture risk adjusted for known risk factors for fractures, estimated GFR, and rapid decline in estimated GFR (>= 5%/yr). Results There were 276 hip and pelvic fractures during a mean of 4.6 years of follow-up. Participants with baseline albuminuria had a significantly increased risk of fracture compared with participants without albuminuria (unadjusted hazard ratio=1.62 [1.22, 2.15], P<0.001; adjusted hazard ratio=1.36 [1.01, 1.84], P=0.05). A dose-dependent relationship was observed, with macroalbuminuria having a large fracture risk (unadjusted hazard ratio=2.01 [1.21, 3.35], P=0.007; adjusted hazard ratio=1.71 [1.007, 2.91], P=0.05) and microalbuminuria associating with borderline or no statistical significance (unadjusted hazard ratio=1.52 [1.10, 2.09], P=0.01; adjusted hazard ratio=1.28 [0.92, 1.78], P=0.15). Estimated GFR was not a predictor of fracture in any model, but rapid loss of estimated GFR over the first 2 years of follow-up predicted subsequent fracture (adjusted hazard ratio=1.47 [1.05, 2.04], P=0.02). Conclusions Albuminuria, especially macroalbuminuria, and rapid decline of estimated GFR predict hip and pelvic fractures. These findings support a theoretical model of a relationship between underlying causes of microalbuminuria and bone disease. Clin J Am Soc Nephrol 8: 233-240, 2013. doi: 10.2215/CJN.06640712
引用
收藏
页码:233 / 240
页数:8
相关论文
共 27 条
  • [1] Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes
    Aso, Y
    Inukai, T
    Tayama, K
    Takemura, Y
    [J]. ACTA DIABETOLOGICA, 2000, 37 (02) : 87 - 92
  • [2] The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: The cardiovascular health study
    Barzilay, JI
    Peterson, D
    Cushman, M
    Heckbert, SR
    Cao, JJ
    Blaum, C
    Tracy, RP
    Klein, R
    Herrington, DM
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (01) : 25 - 34
  • [3] Vascular biology and the skeleton
    Brandi, ML
    Collin-Osdoby, P
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (02) : 183 - 192
  • [4] CHANGES IN TRABECULAR BONE, HEMATOPOIESIS AND BONE-MARROW VESSELS IN APLASTIC-ANEMIA, PRIMARY OSTEOPOROSIS, AND OLD-AGE - A COMPARATIVE HISTOMORPHOMETRIC STUDY
    BURKHARDT, R
    KETTNER, G
    BOHM, W
    SCHMIDMEIER, M
    SCHLAG, R
    FRISCH, B
    MALLMANN, B
    EISENMENGER, W
    GILG, T
    [J]. BONE, 1987, 8 (03) : 157 - 164
  • [5] Urine Volume and Change in Estimated GFR in a Community-Based Cohort Study
    Clark, William F.
    Sontrop, Jessica M.
    Macnab, Jennifer.
    Surf, Rita S.
    Moist, Louise
    Salvadori, Marina
    Garg, Amit X.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (11): : 2634 - 2641
  • [6] Cardiovascular disease and bone
    Eastell, Richard
    Newman, Chris
    Crossman, David C.
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2010, 503 (01) : 78 - 83
  • [7] Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III
    Garg, AX
    Kiberd, BA
    Clark, WF
    Haynes, RB
    Clase, CM
    [J]. KIDNEY INTERNATIONAL, 2002, 61 (06) : 2165 - 2175
  • [8] Compromised bone marrow perfusion in osteoporosis
    Griffith, James F.
    Yeung, David K. W.
    Tsang, Polly H.
    Choi, Kai C.
    Kwok, Timothy C. Y.
    Ahuja, Anil T.
    Leung, Kwok S.
    Leung, Ping C.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (07) : 1068 - 1075
  • [9] Reduced Bone Perfusion in Osteoporosis: Likely Causes in an Ovariectomy Rat Model
    Griffith, James F.
    Wang, Yi-Xiang J.
    Zhou, Hua
    Kwong, Wing Hang
    Wong, Wing Tak
    Sun, Yan-Lin
    Huang, Yu
    Yeung, David K. W.
    Qin, Ling
    Ahuja, Anil T.
    [J]. RADIOLOGY, 2010, 254 (03) : 739 - 746
  • [10] Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: Dynamic contrast-enhanced MR imaging and spectroscopy
    Griffith, JF
    Yeung, DKW
    Antonio, GE
    Lee, FKH
    Hong, AWL
    Wong, SYS
    Lau, EMC
    Leung, PC
    [J]. RADIOLOGY, 2005, 236 (03) : 945 - 951